Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (TEAEs) being mild or moderate in severity, and the ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

COMPASS Pathways CMPS shares are up during Tuesday’s premarket session following the company’s announcement of achieving the ...

The net proceeds from these warrant exercises, along with the net proceeds of approximately $141 million from the recent public offering that closed on February 20, 2026, and its existing cash and ...

Today, Compass updated investors on its drug trial progress, and the stock shot higher. Compass announced two Phase 3 trials ...

LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

Feb 17 () - ‌Drug ‌developer Compass ​Pathways said on ‌Tuesday ⁠its ⁠psilocybin-based ​depression ​therapy ​met ‌the main ...